Abstract
Graves’ hyperthyroidism (GH) in pregnancy affects less than 0.5% of pregnant women. Prior to the advent of antithyroid drugs (ATDs) in the 1940s, GH perinatal mortality was as high as 45%. Perinatal mortality has improved significantly and in 2011 was reported at 1.7%. By making an early diagnosis of GH and maintaining euthyroidism during pregnancy, the physician can reduce the risk of complications to the mother, fetus, and newborn.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
